Oralead Pharma announced that it has received tens of millions of yuan in round of funding on January 29, 2024. The transaction included participation from new investors HighLight Capital, Shenzhen Qianhai BangQin Investment Co., Ltd., Shenyang Borui Pharmaceutical Co., Ltd., and BrightGene Bio-Medical Technology Co., Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
38.4 CNY | +1.56% | +10.12% | +9.71% |
07/05 | China Shares Rise as Property Market Gets Relief; BrightGene Jumps 7% | MT |
07/05 | BrightGene to Sell 500 Million Yuan Shares to Actual Controller; Shares Up 3% | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.71% | 2.21B | |
+38.13% | 705B | |
+32.82% | 583B | |
-3.57% | 364B | |
+20.25% | 332B | |
+5.17% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+8.91% | 169B |
- Stock Market
- Equities
- 688166 Stock
- News BrightGene Bio-Medical Technology Co., Ltd.
- Oralead Pharma announced that it has received funding from HighLight Capital, Shenzhen Qianhai BangQin Investment Co., Ltd., BrightGene Bio-Medical Technology Co., Ltd., Shenyang Borui Pharmaceutical Co., Ltd.